Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-2 Pulsed DC Vaccine in High Risk Breast Cancer Post Neoadjuvant Chemotherapy
NCT02061423Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2014
- Primary completion
- Feb 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of her2 peptide-pulsed dendritic cells in breast cancer, sponsored by Moffitt Cancer Center. Primary endpoints: Participation Compliance at 18 months and Occurrence of Treatment Related Adverse Events at 18 months. Started Apr 2014; status: completed.
02
Drugs
her2 peptide-pulsed dendritic cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02061423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061423.